Overall response rates (ORRs) for patients by treatment group
| Group . | ORR, n/N (%) . | CR/CRi, n/N (%) . | CR rate, n/N (%) . |
|---|---|---|---|
| Off-trial venetoclax patients | 22/33 (66.7) | 19/33 (57.6) | 13/33 (39.4) |
| Off-trial venetoclax patients who received at least 1 day of therapy | 22/30 (73.3) | 19/30 (63.3) | 13/30 (43.3) |
| Off-trial venetoclax patients without prior hypomethylating agent | 20/26 (76.9) | 19/26 (73.1) | 12/26 (46.2) |
| Off-trial venetoclax patients with prior hypomethylating agent | 2/4 (50) | 0/4 (0) | 0/4 (0) |
| Clinical trial patients | 30/33 (90.9) | 28/33 (84.9) | 20/33 (60.6) |
| Group . | ORR, n/N (%) . | CR/CRi, n/N (%) . | CR rate, n/N (%) . |
|---|---|---|---|
| Off-trial venetoclax patients | 22/33 (66.7) | 19/33 (57.6) | 13/33 (39.4) |
| Off-trial venetoclax patients who received at least 1 day of therapy | 22/30 (73.3) | 19/30 (63.3) | 13/30 (43.3) |
| Off-trial venetoclax patients without prior hypomethylating agent | 20/26 (76.9) | 19/26 (73.1) | 12/26 (46.2) |
| Off-trial venetoclax patients with prior hypomethylating agent | 2/4 (50) | 0/4 (0) | 0/4 (0) |
| Clinical trial patients | 30/33 (90.9) | 28/33 (84.9) | 20/33 (60.6) |